Menu
PacPremier
Magic Hour
Montecito
SoCal Gas
Loading...
You are here:  Home  >  'biosimilars'
Latest

Amgen goes full speed ahead on biosimilar drugs

By   /  Friday, October 15th, 2021  /  Banking & Finance, Biotech, Central Coast Health Watch, East Ventura County, Latest news, middle, Subscriber content, Technology, Top Stories, Tri-County Economy, Tri-County Public Companies  /  Comments Off on Amgen goes full speed ahead on biosimilar drugs

This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.

Read More →
Latest

Amgen agrees to develop biosimilars for Chinese market

By   /  Tuesday, September 26th, 2017  /  Central Coast Health Watch, East Ventura County, Latest news, Technology  /  Comments Off on Amgen agrees to develop biosimilars for Chinese market

Increasing its global footprint in the biosimilars market, Amgen announced Sept. 26 that it had formed an exclusive co-development agreement with Chinese drug manufacturer Simcere Pharmaceutical Group. The agreement aims to bring four oncology and inflammation biosimilars in Amgen’s portfolio to commercialization in China. The Thousand Oaks-based biotechnology company will produce and submit approval applications Read More →

Read More →
Latest

Amgen partnering with Japanese company to develop biosimilars

By   /  Thursday, July 14th, 2016  /  Central Coast Health Watch, Latest news  /  Comments Off on Amgen partnering with Japanese company to develop biosimilars

Thousand Oaks-based biotech giant Amgen said July 13 it will partner with a Japanese company to develop and commercialize biosimilars in Japan. Under the partnership, Amgen will develop and manufacture biosimilars while Daiichi Sankyo will obtain marketing approval, distribution and commercialization rights in Japan for the products. The deal also includes several late-stage development drugs. Read More →

Read More →
Latest

Amgen seeks European OK of biosimilar drug, partners with Merck on studies

By   /  Friday, December 4th, 2015  /  Central Coast Health Watch, East Ventura County, Latest news, Tri-County Public Companies  /  Comments Off on Amgen seeks European OK of biosimilar drug, partners with Merck on studies

Amgen announced two developments Dec. 4 that should help the Thousand Oaks-based biotech giant compete. Amgen said it is seeking approval from the European Medicines Agency for ABP 501, a biosimilar drug similar to Humira. Amgen also announced a partnership with New Jersey-based pharmaceutical Merck to partner in a non-Hodgkins lymphoma study using drugs from Read More →

Read More →
Latest

Amgen bipolar about biosimilars

By   /  Friday, December 4th, 2015  /  Central Coast Health Watch, Latest news, Top Stories, Tri-County Public Companies  /  Comments Off on Amgen bipolar about biosimilars

This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.

Read More →
Latest

Amgen touts positive results with new heart health drug

By   /  Friday, March 20th, 2015  /  Central Coast Health Watch, East Ventura County, Latest news, Technology, Top Stories, Tri-County Public Companies  /  Comments Off on Amgen touts positive results with new heart health drug

If approved, it will be the Thousand Oaks-based biotech giant’s first new drug on the market since the FDA’s landmark approval of the first-ever biosimilar drug on the American market.

Read More →
Latest

Amgen’s portfolio threatened as FDA paves path for lower-cost drugs

By   /  Friday, March 6th, 2015  /  Latest news, Technology, Top Stories, Tri-County Public Companies  /  Comments Off on Amgen’s portfolio threatened as FDA paves path for lower-cost drugs

Zarxio, the first biopharmaceutical copycat approved in the U.S., will pave the way for lower-cost alternatives to existing treatments.

Read More →